Rotigotine, a dopamine agonist used for Parkinson's disease (transdermal patch), showed surprising kidney benefits in a pilot study and is now entering Phase 2 for ADPKD in France.
Background
The connection between dopamine and PKD is unexpected but biologically elegant. Polycystins (PC1 and PC2) normally function as mechanosensors in blood vessel endothelial cells and kidney tubular cells. When polycystins are deficient, endothelial cells lose their ability to sense blood flow and produce nitric oxide (NO) — contributing to hypertension and vascular problems in PKD. Researchers in Rouen, France discovered that dopamine D5 receptor stimulation can restore this mechanosensitivity even when polycystins are absent, effectively bypassing the genetic defect.
How It Works
Rotigotine is a dopamine D1/D2/D3/D5 receptor agonist delivered via transdermal patch. In PKD, the relevant target is the D5 receptor on endothelial and tubular cells. D5 activation restores calcium signaling and NO production that's normally triggered by polycystin-mediated flow sensing. The prior IMPROVE-PKD study showed that just 2 months of rotigotine improved endothelial function markers. The ETERNAL-PKD trial will test whether longer-term treatment translates to kidney protection.
Clinical Trial Details
ETERNAL-PKD (NCT06291116) is a Phase 2 trial at University Hospital Rouen, France. It will test rotigotine transdermal patch in ADPKD patients. Not yet recruiting as of mid-2026, with expected start in March 2026 and completion in 2028. The study design and enrollment target have not been fully disclosed.
Why It's Promising
This is a creative repurposing of an existing drug with a solid mechanistic rationale. If dopamine agonism can bypass the polycystin defect, it opens an entirely new therapeutic avenue. The transdermal patch delivery is convenient. However, this targets vascular/endothelial dysfunction rather than cyst growth directly.
Limitations & Concerns
Not yet recruiting — timeline uncertain. Dopamine agonists have significant side effects (nausea, dizziness, impulse control disorders). The IMPROVE-PKD study was very small and short. Targeting endothelial function may not translate to cyst reduction or kidney preservation.